Abstract: A disposable and multiconfigurational animal habitat for obtaining physiological measurements of a small mammal is provided. The habitat includes a disposable and vertically oriented tower having a top, middle, and a bottom section. The tower includes a first chamber and a second chamber. The first chamber is sized, shaped, and configured to house the small mammal and is disposed in the top section of the tower. A first instrumentation platform is disposed in the first chamber and configured to support the small mammal. The second chamber is also sized, shaped, and configured to house the small mammal and disposed underneath the first instrumentation platform. A second instrumentation platform disposed in the second chamber and configured to support the small mammal. The habitat can be assembled from a kit comprising sheet of foldable disposable material having cut-outs and fold lines that can be folded to form the tower of the habitat.

Abstract: An apparatus for non-invasively measuring an electrocardiogram (ECG) in a conscious ambulatory subject includes an electrically conductive platform. The electrically conductive platform establishes an electrical connection with the subject at one of a position forward (e.g., rostral to) or a position rearward (e.g., caudal to) the heart. An additional electrical connection is established at the other of a position forward (e.g., rostral to) or a position rearward (e.g., caudal to) on the subject. The position rearward to (e.g., caudal to) the heart can be the tail of the subject. The additional electrical connection can be established by a movable electrode, an electrically conductive ringlet, an additional electrically conductive platform, a region of conductive material, an electrically conductive dome, a food element, or one or more electrically conductive posts.

Abstract: The present invention provides methods of using halogenated volatile compounds, e.g., halogenated ether, for treating a neurological disorder, e.g., Parkinson's disease.

Abstract: The mdx mouse is a model of Duchenne muscular dystrophy. The present invention describes that mdx mice exhibited clinically relevant cardiac phenotypes. A non-invasive method of recording electrocardiograms (ECGs) was used to a study mdx mice (n=15) and control mice (n=15). The mdx mice had significant tachycardia, consistent with observations in patients with muscular dystrophy. Heart-rate was nearly 15% faster in mdx mice than control mice (P<0.01). ECGs revealed significant shortening of the rate-corrected QT interval duration (QTc) in mdx mice compared to control mice (P<0.05). PR interval duration were shorter at baseline in mdx compared to control mice (P<0.05). The muscarinic antagonist atropine significantly increased heart-rate and decreased PR interval duration in C57 mice. Paradoxically, atropine significantly decreased heart-rate and increased PR interval duration in all mdx mice.

Abstract: The mdx mouse is a model of Duchenne muscular dystrophy. The present invention describes that mdx mice exhibited clinically relevant cardiac phenotypes. A non-invasive method of recording electrocardiograms (ECGs) was used to a study mdx mice (n=15) and control mice (n=15). The mdx mice had significant tachycardia, consistent with observations in patients with muscular dystrophy. Heart-rate was nearly 15% faster in mdx mice than control mice (P<0.01). ECGs revealed significant shortening of the rate-corrected QT interval duration (QTc) in mdx mice compared to control mice (P<0.05). PR interval duration were shorter at baseline in mdx compared to control mice (P<0.05). The muscarinic antagonist atropine significantly increased heart-rate and decreased PR interval duration in C57 mice. Paradoxically, atropine significantly decreased heart-rate and increased PR interval duration in all mdx mice.